Stage at diagnosis only partly explains the wide variation in lung cancer survival rates among different developed countries, indicates a large study of nearly 60,000 patients, published online in Thorax.
Feb 12, 2013
0
0
SUVmax (Maximum Standardized Uptake Value) may be a significant and clinically independent marker to indicate progression-free survival in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body ...
Feb 8, 2013
0
0
For patients with medically operable clinical stage I non–small-cell lung cancer (NSCLC), lobectomy or pneumonectomy is the standard approach. For patients with medically inoperable stage I NSCLC, stereotactic body radiotherapy ...
Jan 15, 2013
0
0
Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), may prolong survival of selected patients based on tumor biomarkers. The presence ...
Jan 15, 2013
0
0
Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their ...
Jan 15, 2013
0
0
Favorable results have led to crizotinib gaining approval for the treatment of advanced stage ALK-positive non-small cell lung cancer (NSCLC) in Japan, the United States, Canada, and several other countries in Europe and ...
Dec 15, 2012
0
0
Lung cancer researchers at St. Joseph's Hospital and Medical Center in Phoenix, Ariz., in collaboration with researchers at the Translational Genomics Research Institute and other institutions, have identified a gene that ...
Nov 29, 2012
0
0
Targeted cancer therapy has been transforming the care of patients with non-small-cell lung cancer (NSCLC). It is now standard practice for tumor specimens from NSCLC patients to be examined for EGFR mutations and ALK rearrangements ...
Nov 15, 2012
0
0
It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent ...
Nov 15, 2012
0
0
Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib ...
Nov 15, 2012
0
0
